Shots:

• The company has completed the patient enrollment in P-II study to evaluate Nykode’s  VB10.16 + Roche’s atezolizumab (checkpoint inhibitor) in 50 patients with advanced or recurrent, non-resectable HPV16-positive cervical cancer who failed or are not eligible for current SoC across 20 sites in 6 EU countries
• The company is expected an interim efficacy and safety data from the first patients in H1’22 & is also planning to evaluate VB10.16 in other HPV-driven cancers, including head and neck cancer
• VB10.16 is an off-the-shelf therapeutic HPV16 cancer vaccine that is designed to induce strong HPV16 specific T cell responses for the treatment of HPV16-positive cancers

to­ Ref: Globenewswire | Image: Linkedin